Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PD-1/L1
Pharma
Merck's Keytruda stages comeback in head and neck cancer
Merck & Co. hopes a new positive readout can return Keytruda to glory in head and neck cancer about two years after a prior failure.
Angus Liu
Oct 8, 2024 10:26am
BeiGene launches PD-1 drug Tevimbra at 10% discount to Keytruda
Oct 4, 2024 10:37am
BMS' Opdivo widens lung cancer reach with perioperative FDA nod
Oct 3, 2024 3:54pm
Experts back FDA's plan to restrict PD-1 drugs in GI cancers
Sep 26, 2024 1:38pm
FDA challenges broad use of PD-1 drugs in stomach cancer
Sep 24, 2024 2:30pm
Exelixis plots FDA prostate cancer filing despite survival miss
Sep 16, 2024 5:00pm